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Abstract: Synthetic biology is a rapidly growing multidisciplinary branch of science which aims
to mimic complex biological systems by creating similar forms. Constructing an artificial system
requires optimization at the gene and protein levels to allow the formation of entire biological
pathways. Advances in cell-free synthetic biology have helped in discovering new genes, proteins,
and pathways bypassing the complexity of the complex pathway interactions in living cells.
Furthermore, this method is cost- and time-effective with access to the cellular protein factory
without the membrane boundaries. The freedom of design, full automation, and mimicking of in vivo
systems reveal advantages of synthetic biology that can improve the molecular understanding of
processes, relevant for life science applications. In parallel, in vitro approaches have enhanced our
understanding of the living system. This review highlights the recent evolution of cell-free gene
design, proteins, and cells integrated with microfluidic platforms as a promising technology, which
has allowed for the transformation of the concept of bioprocesses. Although several challenges
remain, the manipulation of biological synthetic machinery in microfluidic devices as suitable ‘homes’
for in vitro protein synthesis has been proposed as a pioneering approach for the development of new
platforms, relevant in biomedical and diagnostic contexts towards even the sensing and monitoring
of environmental issues.
Keywords: synthetic biology; microfluidics; de novo gene synthesis; cell-free protein synthesis
1. Introduction
Synthetic biology is a rapidly growing field that covers several disciplines including molecular
biology, chemistry, physics, mathematics, engineering, and nanotechnology. The power of synthetic
biology derives from the inspiration and diversity of living biological systems. The unique property
of synthetic biology is the ability to design and build new semisynthetic systems to modify
the system’s functionality or to perform new functions that the biological system is not able to
perform naturally to meet desired needs [1–3]. Rapid advances in DNA sequencing and gene
technologies have a direct impact on the progress of synthetic biology in terms of the ability to
reprogram the cell [4]. However, the molecular toolkit for synthetic biology includes RNA, DNA,
and proteins. Two to ten molecules from this toolkit are typically assembled in order to build a
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system that is able to perform the desired function when transplanted into a seminatural context.
This construction process is complex as it needs genetic reprogramming, DNA and protein synthesis,
and functional screening [5]. Understanding how life works is the main challenge in synthetic biology.
The complexity of the biological systems and lack of knowledge make it difficult to mimic living
systems. Indeed, uncontrolled interference between native and artificial components may affect the
behavior of the artificial system by making it different to the biological one.
Synthetic biology research involves basically four points: (1) designing an artificial system, which
usually is inspired from nature; (2) system construction using biological and nonbiological elements;
(3) testing the developed system to confirm its functionality; and (4) analysis to determine the degree to
which the manipulated system mimics the functional and structural properties of the natural system [5].
Recent research in synthetic biology has focused on the construction of genetic circuits, biological
modules, and synthetic pathways in genetically reprogrammed organisms [1,3]. Combining two or
more fields provides promising opportunities for diagnosis, development of genetic processing devices,
high-throughput analysis of mutant libraries, high-resolution single cell analysis, and isolation and
characterization of mutant or rare microbes or genes [6–8].
Integration of multidisciplinary techniques, such as de novo DNA synthesis, cell-free protein
expression, and microfluidics, could contribute significantly to the field of synthetic biology by saving
time and cost as well as improving the functionality of a developed system by making it robust
and effective. In this review, cell-free gene and protein synthesis systems and their applications in
microfluidic technology are discussed. The basic principles of cell-free protein expression systems are
described with emphasis on the most commonly used systems. Constructing artificial cells from the
bottom-up approach using biological and nonbiological building blocks, such as lipids and proteins,
as well as using cellular machinery integrated with a microfluidic platform are also reported. This work
presents microfluidic technology and its applications in synthetic biology as a promising platform to
simplify cellular structure and functions, which can be used for engineering biological parts at protein
and cell levels.
2. Cell-Free Protein Synthesis
Cell-free (also known as in vitro) protein synthesis technology is a powerful alternative system
to the cell-based (in vivo) system and exploits the cellular protein machinery to synthesize proteins
directly outside living cells [9–11]. Table 1 summarizes the advantages and disadvantages of both
systems. In the cell-free system, mixing exogenous mRNA or DNA with crude extract or lysate from
any cell origin provides easily controllable transcription–translation machinery in an open environment
(Figure 1). Several organisms have been used to prepare a lysate that contains all necessary enzymes
and cellular factors needed for the protein expression machinery. Exogenous supplies of nucleotide,
salts, essential amino acids, and energy-generating factors are also needed to develop a cell-free
system [9,12]. The common commercial lysates available are Escherichia coli, yeast, rabbit reticulocyte,
wheat germ, and insects (Table 2). The choice of extract source depends mainly on the origin of the
desired protein to be expressed, its complexity, and further downstream applications. This choice is
important and should be carefully considered as it affects the quantity of protein and generation of
incomplete polypeptides or full-length proteins [12,13]. Another important factor that can significantly
affect protein expression is the use of genetic templates. In coupled systems, DNA is used as a template
encoding the target protein, while the mRNA template generated by in vitro transcription or from
native sources is used in uncoupled systems. A plasmid or polymerase chain reaction (PCR) fragment
can be used as a DNA template, although this must contain a promoter, such as T3, T7, or SP6, and a
ribosomal binding site (RBS) that acts as a translation initiation signal, such as a Shine–Dalgarno or
Kozak sequence, to generate prokaryotic or eukaryotic proteins, respectively [9].
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Figure 1. Cell-free protein expression system. The system requires a genetic template, e.g., DNA, that 
is composed of a promoter, a ribosomal binding site (RBS) which is either a Shine–Dalgarno or Kozak 
sequence, and a translation–transcription termination region. The reaction needs cell lysate and an 
energy regeneration system. 
Table 1. Comparing between cell-free and cell-based protein expression systems [4,9–16]. 
Cell-Based System Versus Cell-Free System 
Yes Needs cloning No 
No Ability to produce toxic protein Yes 
No Ability to express multiple genes Yes 
No Usually generate functional, soluble, and folded proteins Yes 
No 
Possible adjusting and controlling by the addition of helper 
molecules 
Yes 
No 
Possible incorporation of non-natural or chemically modified 
amino acids 
Yes 
Yes Native environment No 
Days Time Hours 
Low Costs High 
Table 2. Comparison of different cell-free protein expression systems [9,12,17–24]. 
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Extract 
Rabbit Reticulocyte Lysate Wheat Germ Extract Yeast Cells, Tumor Cells, 
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proteins 
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Prokaryotic (bacteria, 
mammalian virus, plant virus), 
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Prokaryotic (bacteria, 
plant virus), Eukaryotic 
(plants, animals) 
- 
Genetic 
modification tools Well established Poor Poor Poor 
Extract preparation Simple 
Requires complex manipulation 
of animal tissues but cell 
breakage is easy and fast 
Complex and time- 
consuming 
Cell cultivation is complex 
and time-consuming, but cell 
breakage is easy and fast 
Cost Low High Low High 
The cell-free protein synthesis system offers many advantages compared with the cell-based 
systems, including high protein yield; generation of soluble and functional proteins without 
inhibition of regulatory pathways; the possibility of using mRNA or PCR fragments directly without 
any need for cloning; and the possibility of expressing multiple templates, which permits the 
Figure 1. Cell-free protein expression system. The system requires a genetic template, e.g., DNA, that
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The cell-free protein synthesis system offers many advantages compared with the cell-based
systems, including high protein yield; generation of soluble and functional proteins without inhibition
of regulatory pathways; the possibility of using mRNA or PCR fragments directly without any need
for cloning; and the possibility of expressing multiple templates, which permits the production of
the protein population in a single reaction [9,12,13]. Many proteins are unstable, proteolytically
sensitive, or toxic, while in other cases, living cells cannot tolerate these proteins physiologically.
Such proteins cannot be synthesized by a cell-based system, although they can be synthesized with
the cell-free system [19,20]. Moreover, in the cell-based system, many proteins need post-translational
modification to generate active proteins. In contrast, the cell-free system allows the addition of helper
molecules which will improve protein folding and functionality. For example, dithiothreitol (DTT) is
usually added to the cell-free system to increase protein expression and to preserve the cytoplasmic
environment. DTT slightly affects the folding of cytoplasmic proteins and significantly affects the
folding of proteins that form disulfide bonds for activity. Furthermore, the open nature of this system
allows the incorporation of non-natural or chemically modified amino acids at specific positions during
translation, which leads to the generation of novel proteins [9,17].
Apart from the crude extract containing the basic translation–transcription components,
the protein synthesis using recombinant elements (PURE) system consisting of reconstituted, purified
elements derived from the E. coli translation machinery is another option to express cell-free proteins.
The PURE system reconstitutes the translation–transcription process from 31 purified recombinant
proteins, 46 tRNAs essential substrates, and corresponding enzymes [18,19]. This system is adapted for
in vitro protein selection and for library display. However, time, cost, and incomplete understanding
of fundamental biology restrict the construction of the PURE system. Matsuura et al. [25] designed a
computational model to investigate the dynamic features of large-scale biological reaction networks
based on E. coli-based reconstituted in vitro protein synthesis. The developed model synthesized
a peptide (Met-Gly-Gly) based on the components of the PURE system and kinetic parameters
collected from the literature to simulate the reaction. The obtained model consisted of 241 components
and 968 reactions and achieved a steady state in <1 min. Reyes et al. [26] designed a set of T7
promoters to express the protein in reconstituted and E. coli-extracted-based cell-free systems at
different transcriptional rates. The expression level and the rate of protein production in response to
transcription rate change were different in the two cell-free systems. Indeed, a simple mathematical
model for the two cell-free systems was constructed to confirm that the changes in the transcription
rate are driven by different expression dynamics. Several limiting factors that affect protein expression
and reproducibility of the experimental data were investigated in this model. For the cell-free protein
synthesis system, unwanted activities during protein synthesis are the main disadvantage of this
system [1,27]. Continuous protein production is limited by the supply of exogenous materials, such as
amino acids and nucleotides, and the accumulation of products.
There are different cell-free protein synthesis reaction formats; the main two modes are batch and
dialysis. The batch reactions are based on performing cell-free transcription/translation reactions in one
vessel containing all the required elements. Although this mode is easy to handle, fast, and scalable,
it has short reaction times which lead to limited protein production (micrograms per mL) due to
component degradation and inhibitor accumulation, such as free phosphate and Mg2+ [28]. In contrast,
the cell-free continuous-exchange mode can be optimized to prolong the reaction lifetime and increase
protein production (milligrams per mL). In this reaction, transcription/translation coupled reactions
are performed in one chamber but are separated from the reaction reservoir by a semipermeable
dialysis membrane with a cutoff at 10–15 kDa. The reservoir continuously feeds the chamber with
low-molecular-weight substrates including nucleotides, amino acids, ions, and energy resources and
allow dilution of the by-products from the reaction chamber via the dialysis membrane, extending
the reaction lifetime [20,29–31]. Different reactors in the integrated dialysis system of cell-free protein
synthesis have been used including a dialysis bag clamped at both ends [32] and commercial devices
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from several suppliers, such as a rapid translation system (RTS) cell-free kit from Roche [33] and
DispoDialyzer from Spectrum Laboratories, Inc. [34].
In synthetic biology, the cell-free protein expression system is exploited to construct membrane
proteins in view of artificial cellular components, such as protein-functionalized membranes.
Damiati et al. [35] developed one such approach in this direction, aiming to reconstitute the
voltage-dependent anion channel (VDAC) protein into a synthetic membrane. The VDAC proteins
were synthesized by a bacterial cell lysate, either in direct contact with a planar synthetic
bioarchitecture of a membrane or synthesized and purified before exposure to the lipid membrane.
The favorable surface-to-volume ratio in a microfluidic system had been previously investigated by our
group [36–39]. The formation of the artificial membrane and reconstitution of the VDAC protein was
monitored by quartz crystal microbalance with dissipation monitoring (QCM-D) and electrochemical
impedance spectroscopy (EIS). In the first strategy, VDAC genetic materials were mixed with the
translation–transcription machinery reaction mixture in the presence of the artificial membrane in
order to allow immediate incorporation of the synthesized protein molecules once generated. QCM-D
and EIS measurements showed degradation of the formed membrane architecture, which may be
attributed to the interaction between the cell lysate and the synthetic membrane due to the molecular
crowding of the cell-free extract mixture and the detergent-like environment. In contrast, purified
VDAC proteins expressed by the cell-free system can be incorporated into the lipid membrane, which
forms active channels to allow ions to move across the membrane.
The limited lifetime of the translation activity is a disadvantage of cell-free protein expression
system, which leads to low yields of protein expression. Hence, a continuous flow of the cell-free
lysate is proposed as a solution. Thus, microfluidic technology offers a promising approach, since the
microfluidic chamber can not only provide continuous provision of tRNAs but also an energy source,
while removing the educts of synthesis and producing a planar membrane with de novo synthesized
and folded membrane proteins in optimal (physical and chemical) conditions.
3. Microfluidic Technology
Microfluidic devices are widely used as a promising technology that allows analysis of molecular
biology reactions and cell growth on the same platform. Compared with traditional, large-scale
methods, microfluidics use fewer resources (minimum quantity of samples/reagents from microliters
to femtoliters and less consumed), perform experiments rapidly and accurately, decrease cost,
and enable high throughput and automation [40]. Careful design of microfluidic chips can effectively
improve the throughput of the biochemical reaction and analysis. Controlling the geometry enables the
subdivision of channels into multiple functional units, which involves mixers, reactors, detector,
valves, and pumps. Furthermore, shorter microfluidic channels improve rapid heat and mass
transportation [41]. Complex channel geometries promote mixing in microreactors, which leads
to twisting, splitting, and recombining of fluid streams. Laminar flow is the major factor that controls
the diffusion-controlled mixing of components at the interface of converging fluid streams. This is
characterized by a low Reynolds (Re) number and organizes the flow rate of multiple fluids in parallel
without turbulence in a single channel [42,43]. Several techniques are available that enable mixing
of fluids and samples in microfluidic devices. Hydrodynamic flow focusing (HFF) is one of the
most ultra-fast mixing methods that can be precisely achieve with a laminar mixer (Figure 2A) [44].
The main disadvantage of the diffusion-based microfluidics is related to the number of unreacted
materials; this can be overcome by a microfluidic mixer (Figure 2B). Indeed, droplet-based microfluidics
offers an alternative technique which allows independent reactions to occur within the droplets
(Figure 2C) [45–47]. In synthetic biology, cells can be encapsulated into the generated droplets or
the droplet itself can be exploited as a cell architecture. Thus, microfluidic devices are widely used
to perform biological and chemical experiments [48,49]. Several materials are available to fabricate
microfluidics devices, such as polymers (e.g., polydimethylsiloxane (PDMS)), metals, glass silicon,
and ceramics. The material choice depends on the required temperature and pressure, utilization of
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corrosive fluids, and the desired application [50,51]. Furthermore, microfluidic chips can be designed
by the integration of PCR machines, cell sorters, and detectors [52–54].Genes 2018, 9, x FOR PEER REVIEW  6 of 16 
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4. icrofluidic Platfor s and Cell-Free Applications
4.1. De Novo Gene Synthesis in Microfluidics
Microfluidic technology is proposed as a promising alternative to the traditional macroscale and
microarray techniques for synthesizing oligonucleotides and genes with at least a tenfold improvement
in performance [56]. Microfluidics is able to reduce the cost and time of DNA synthesis by integrating
and parallelizing reaction chambers on a single device, minimizing reagents and labor in addition
to enabling several rounds of buffer changes and rinses. An additional advantage of microfluidics
is the ability to integrate each chamber with special capabilities (e.g., valves) to control the reaction
easily [57–61]. Due to the incompatibility of polydimethylsiloxane (PDMA) with convenient DNA
synthesis chemistry, microfluidic devices for de novo gene synthesis are usually formed or coated with
resistant materials such as Teflon [62].
Microfluidics enables the accumulation of minimum quantities of genetic materials, which
creates a single-cell resolution to study DNA sequencing and to analyze gene expression.
An electrophoresis-based sequencing microchip was developed successfully by Fredlake et al. [63].
Compared with convenient capillary array electrophoresis instruments, the fabricated chip offered
ultrafast DNA sequencing with an efficient approach for separating DNA fragments and reading
lengths of up to 600 bases in 6.5 min. Lee et al. [58] reported on the successful fabrication of a
microfluidic device that directly generates ~200 bp DNA constructs without any additional step
for concentrating or amplifying the genetic materials. This device was able to reduce the reagent
consumption by 100-fold and was able to synthesize ~100 pmol of the oligonucleotide sequence.
Such direct synthesis reduces cost and time, while this method also eliminates the incorporation
of errors into the full-length sequence during the amplification procedure. Another obstacle on
the genome-scale solved by microfluidic devices is the limited quantity of the biological sample.
Current microarray techniques for monitoring mRNA transcription levels need nanogram amounts
of total RNA. Irimia et al. [64] fabricated a microfluidic device which enables RNA preparation and
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gene expression from a biological sample that contains ~150 cells. All steps, including cell lysis, RNase
inactivation, and DNA and protein digestion, were performed on a single chip and the extracted
material was enough for further transcriptome analysis.
Traditional de novo gene synthesis techniques usually yield a pool of DNA fragments with limited
sizes and require further assembly steps to ligate these short fragments into larger constructs [65,66].
On the contrary, microfluidics technology enables the rapid mixing of a selection of gene fragments and
assembly of reagents in separated droplets to generate combinatorial libraries. A digital microfluidic
device developed by Yehzekel et al. [67] was used for de novo synthesis, combinatorial assembly,
and cell-free cloning of DNA libraries in submicroliter reaction droplets (300 nL) through subsequent
additions. In this system, nine oligonucleotides were used as building blocks and approximately
160 bp of synthetic DNA was added to the construct during each polymerization step. Another system
composed of eight DNA fragments and dispensing valves enabled the generation of 1 nL droplets that
contain one type of the DNA fragments. Droplet pairs were collected and dispersed into separate wells
of a microplate and were subsequently merged by centrifugation. These fragments were assembled
by Gibson assembly. This technique was able to generate a 16-plex combinatorial library that was
verified by PCR [68]. Ochs et al. [69] developed a single-layer pincher valving system. In this system,
the microfluidic chip involves several valves that precisely regulate the fluid flow in channels to
control the mixing of four different DNA fragments. Subsequently, this allows the formation of
droplets. The encapsulation of DNA fragments into the droplets occurs with the addition of Golden
Gate assembly reagents and droplets collected in a PCR tube, which undergoes further assembly
reaction. Two microfluidic devices used modern DNA assembly methods (Gibson and Golden Gate).
These methods have the ability for on-chip DNA construction because they omit any additional
washing steps or subsequent addition of reagents [45]. The microfluidics of droplets has been exploited
as an alternative to whole-genome sequencing, in which the genomic region of interest can be targeted
and amplified for further sequencing. Tewhey et al. [70] developed a microfluidic droplet system
which can perform up to 1.5 million PCR reactions in parallel, presenting a significant improvement in
the experimental throughput.
The successful construction of DNA depends mainly on the quality of DNA fragments, required
purification, and assembly processes. Hence, further efforts are needed to develop microfluidic devices
that allow preparation, synthesis, purification, and assembly on a single chip. The fully integrated
system could be a promising research tool for gene construction and screening.
An alternate, versatile platform for synthetic biology, paper-based synthetic gene networks were
developed by Pardee et al. [71] for in vitro applications in health, clinics, research, and industry.
In this model, the enzymes of transcription/translation reactions were combined with engineered
gene circuits. Subsequently, the cell-free synthetic gene networks were embedded onto cellulose
paper by freeze-drying pellets of the cell-free expression system and other porous materials which
can be activated later by a rehydration reaction. The fabricated circuit was a low-cost, electronic
optical interface that can be detected colorimetrically by the naked eye. Indeed, the resulting abiotic
paper-based platform is a stable, sterile, and portable synthetic gene network external to the cell.
Paper-based microfluidics can be even made more complex, utilizing wax- [72] or glue-assisted
bonding [73]. The possible enzyme and reaction component interactions with the microfluidics
components and the biocompatibility of the material should be taken into account [51].
4.2. Microfluidic Cell-Free Protein Synthesis
The combination of microfluidic technology with cell-free protein synthesis systems improves the
protein synthesis and characterization in parallel to synthetic biology. However, the rapid growth of
genome sequencing has attracted more attention, with a focus on finding the relationship between a
gene and its corresponding protein. Hence, microfluidic devices have been proposed as a promising
environment for the post-genome era, allowing us to run more experiments compared with utilizing the
genome alone [74,75]. The investigation of a protein synthesized by a newly discovered gene is based
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on the availability of a sufficient quantity of the protein. Microfluidic channels and the open nature of
cell-free systems address this problem by providing a continuous supply of nutrients (e.g., nucleotides,
amino acids) and removing by-products. As published by Khnouf et al. [76], a continuous exchange
cell-free protein synthesis device consisting of 96 units to express β-glucuronidase was fabricated.
The solution continuously fed into the microfluidic device increased protein production by up
to 87 times compared with the traditional microplate. Apart from reducing the consumption of
reagents, microfluidic devices allow drug screening and further analysis on the same chip without
any requirement for protein harvesting [76]. A cell-free system with an affinity assay integrated with
a microfluidic platform was developed for large-scale investigations of protein–protein interactions
by Gerber et al. [77]. In this system, the interactions of 43 Streptococcus pneumoniae proteins were
investigated, with this experiment performed in quadruplicate. A total of 14,792 experiments
were performed on the same chip, resulting in the discovery of new physical interactions in the
biochemical pathways.
The integration of a cell-free protein synthesis system with microfluidic chips can be exploited
for therapeutic (produce therapeutic agents) or diagnostic (detect toxins, antigens, cells) purposes.
The generation of therapeutics at the POC, which will provide costly drugs in their pure form,
such as orphan drugs, and personalized medicine, is currently needed [78]. Timm et al. [79] designed
a microfluidic bioreactor, which allows the generation of a single dose of a therapeutic protein.
This footprint device integrates a nanofabricated membrane which enables the exchange of materials
between the cell-free protein reactor and feeder channels to enhance the exchange of energy, metabolites,
and inhibitors. This device improved protein expression quantity and protein rate expression. For toxin
detection, Hugh et al. [80] developed an array device to detect toxins. This device was composed of
three units, with each one consisting of a reaction chamber and a feeding chamber for in vitro synthesis
of three proteins (green fluorescent protein, chloramphenicol acetyl-transferase, and luciferase).
High levels of protein expression were noticed due to the continuous feeding, removal of small
by-products, and absence of inhibitors. When toxin simulants (either tetracycline or cycloheximide)
were added, protein production yield was decreased. Indeed, the fabricated device was used to
detect ricin, a bioterrorism agent that inhibits human protein expression. Ricin has been identified
as inhibiting the production of luciferase. Synthesis of luciferase into the microfluidic chamber was
indicated by luminescence. Luciferase production was decreased with increasing ricin concentration
in the microfluidic channel.
Since the cell-free protein synthesis system is not restricted by physical barriers, it can be
merged with sensor devices for real-time analysis and sensitive characterization of protein functions.
Monitoring techniques are based on fluorescent labeling, optical microcavities, mechanical resonators,
or nanowires [81]. Fluorescent resonance energy transfer (FRET) and fluorescent correlation
spectroscopy (FCS) are examples of fluorescent detection methods. Ridgeway et al. [82] developed a
microfluidic system that uses FRET to monitor the binding kinetics of rRNA and a ribosomal protein.
They also used FCS for a two-photon detection mechanism in order to minimize the photobleaching
of the sample. Moreover, the integration of a cell-free protein system and microfluidic platform with
surface plasmon resonance (SPR) allows in situ investigation of the kinetics of protein interactions
in real time [83,84]. Due to the ability of SPR to detect the mass adsorbed on the surface, Lee et al.
performed cell-free protein synthesis reactions on an SPR chip. The generated protein molecules
were bound to the chip, which generated SPR signals in real time [85]. In another study using the
dual elements of on-chip protein expression and capture methodology, a protein microarray from a
double-stranded DNA (dsDNA) microarray in a microfluidic platform was developed and SPR was
used for bio-sensing measurements [86].
A problem associated with cell-free protein synthesis systems is degradation and hydrolysis of
RNA molecules. A microfluidic Transcription–RNA Immobilization and Transfer–Translation (TRITT)
was developed to overcome this obstacle. The TRITT chip enables cell-free protein synthesis with
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quasi-continuous mRNA transfer under controlled conditions for in vitro translation and transcription
in separated compartments [87].
4.3. Microfluidics and Proteomics
The ability of the cell-free protein synthesis system to generate protein populations in a single
reaction has been exploited to develop proteomic tools, which have been used in protein discovery
in vitro and selection from large, diverse libraries. A proteome is an entire set of proteins that is derived
from the genome directly and is subsequently used to regulate gene expression and cellular metabolism.
The quantitative analysis of a proteome helps us to understand biology at the system level [88,89].
Thus, employing microfluidic devices in proteomic research is widely used for preconcentration,
separation, and single-cell proteomics [89].
An obstacle facing protein research is the generation of a low protein quantity, which can be solved
by a preconcentration step to increase protein concentration to a detectable range. Kelly et al. [90]
developed a membrane-integrated microfluidic chip that concentrated protein. For example,
R-phycoerythrin exceeded the original amount of the protein by 10,000-fold to improve microchip
capillary electrophoresis. Additionally, compared with convenient capillary-based systems, this
electrical field gradient focused on microchip-enhanced proteins, which increased the resolution by
threefold and enriched the florescent-labeled peptide by a factor of >150-fold. A flat nanofluidic filter
within a microchannel was fabricated as a microfluidic sample preconcentration chip. This system is
based on electro-kinetic trapping, in which the nanofluidic filter acts as an ion-selective membrane
that traps charged molecules for several hours with a concentration factor of 106–108 fold [91].
Another system composed of a thin-walled PDMS section between two microchannels enabled the
preconcentration of negatively charged proteins under an electronic field. Protein molecules were
assembled on the anode with an elevated concentration of up to 103–106 fold [92].
To evaluate protein dynamic interactions, it is important to quantify the number of proteins present
in the system, which helps us to study biology at the protein level. Microcapillary electrophoresis (µCE)
is widely used to separate proteins [93,94]. Duffy et al. [95] designed a rapid prototyping PDMS-based
µCE system in less than 24 h. This microfluidic chip allowed the separation of DNA fragments,
amino acids, and charged ladders of positively and negatively charged proteins in aqueous solutions
with a resolution that is comparable to other systems using fused silica capillaries. Two-dimensional
(2D) CE was developed to improve the separation resolution by coupling two separation modes
orthogonally [96]. Li et al. [97] developed an emerged protein concentration/separation system. In this
model, non-native isoelectric focusing was combined with SDS gel electrophoresis on a polycarbonate
microfluidic device. The overall peak capacity of the 2D protein separations was ~1700, which was
obtained in >10 min.
Single-cell proteomics enables the characterization of protein expression in individual
cells, which offers valuable insight for generation within a heterogeneous cellular population.
Microfluidic platforms have attracted attention for single-cell proteomics research due to their ability
for automation and their compatible sizes with cells [88]. McClain et al. [98] fabricated a microfluidic
device that integrates cell handling, cell lysis, electrophoresis separation, and fluorescent detection
on a single chip. The loaded cells were hydrodynamically transferred from a reservoir to a region
where they were concentrated and then rapidly lysed by the pulses from an electric field within
33 ms. This microfluidic system showed a total separation time of 2.2 s. Ros et al. [99] reported on an
integrated microfluidic chip with cross-shaped microchannels for the docking of single cells. Each cell
was manipulated into the docking area by an optical tweezer before the cells were lysed by electrical
pulses. The released protein contents were subsequently separated by electrophoresis and detected by
laser-induced fluorescence.
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4.4. Artificial Cells in Microfluidics
Synthetic biology involves constructing/mimicking the biological system by merging different
fields in order to generate artificial biomimetic cells by reducing complexity, which helps in
understanding the origin of life. To construct artificial cells, two approaches from two opposing
directions can be followed: top-down and bottom-up [100–102]. The top-down method starts
from living cells and descends to generate cells with the minimal genome needed for survival.
The main disadvantages associated with this approach include the difficulty in scaling up, time
cost, and expensiveness [4,103]. In contrast, the bottom-up approach starts with simple biological and
chemical components and ends with a cell composed of the minimal requirements for life with the
ability to perform a desired function [104].
Integrating the bottom-up cell-free systems with microfluidic technology is becoming a powerful
toolbox to engineer seminatural cells [105–107]. These cells are able to self-organize and self-reproduce
to perform functions that exist in nature, such as protein synthesis, and can be used to investigate
biological networks [108,109] or investigate novel functions, such as creating new signal pathways or
synthesizing smart cells that deliver drugs on-site in response to stimulation [23,110]. The cell-free
protein expression system, especially the PURE system, has been recently applied to artificial
cell models. The integration of de novo DNA synthesis with replication in the artificial cells
provides genetic information sustainability in the synthetic system [111]. A critical step in artificial
cell construction involves compartmentalized translation–transcription machinery materials or any
biological elements from the exterior environment. This must be conducted without a loss of
function in order to preserve the genetic information and corresponding phenotype. The physical
barriers can be based on water droplets, polymers, and lipid vesicles [112,113]. Hence, microfluidic
technology allows bioinspired cell-like droplets to be generated and manipulated on chips (Figure 3).
Droplet-based microfluidics offers several advantages, such as mono-dispersity, compartmentalization,
high-throughput generation, and performing of functional operations in droplets [48,114,115].
The designed DNA template and cell-free protein expression system have been successfully
encapsulated into droplets that are generated by microfluidic chips. For example, cell-free green
fluorescent protein was expressed from a single molecule of DNA template into picoliter water-in-oil
(W/O) droplets. The microfluidic reservoir chamber stored ~106 droplets, which were stable for at
least 6 h. This extends the time for further biochemical analysis [116]. A droplet-based microfluidic
system was developed that enabled cell-free MreB, a structural membrane-associated protein, to
maintain the rod-like shape of bacteria. This was encapsulated and expressed into single emulsions.
The generated micrometer-scale protein patches were distributed at the water/oil interface [117].
Ho et al. [118] built a double-emulsion device to allow the combination of plasmid DNA and cell-free
reaction mixture and subsequent synthesis of the mechanosensitive channel protein. This bacterial
protein opens when the membrane is under high tension and decomposes into ultra-thin double
emulsions. Since the cellular membrane has an asymmetric phospholipid bilayer that may allow
lipid–protein interactions, Kamiya et al. [119] developed cell-sized asymmetric lipid vesicles to mimic
biological membrane asymmetry by applying microfluidic flow to a micro-sized planar asymmetric
lipid bilayer. Generation of giant vesicles with asymmetric lipid distribution and a low content of
organic solvents plays a role in membrane protein reconstitution. Synthesis of in vitro membrane
protein into giant asymmetric vesicles enhances the reconstitution ratio of the synthesized proteins.
The differences in the reconstitution rate of membrane proteins into lipid bilayers may attributed to the
electrostatic attraction between the protein and the asymmetric lipid membrane. The generated giant
vesicles exhibited a lipid membrane flip-flop behavior similar to the lipid flip-flop activity noticed in
apoptotic cells.
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Sokolova et al. [120] developed a platform based on W/O droplets that stimulates coacervation of
E. coli cell lysate and following gene expression under crowded or noncrowded conditions. The phase
separation of cell lysate into a lipid coacervate comprising complex mixtures of proteins and other
macromolecules has allowed a direct comparison between mRNA synthesis in dilute and crowded
environments. In a crowded environment, the binding constant of T7 RNA polymerase to DNA
and the rate constant of transcription is significantly improved. The liquid–liquid phase transitions
and production of crowded compartments significantly support in vitro transcription and translation.
Hence, generation of an artificial cell-like environment by coacervation enables synthesis of mRNA
at a high rate and reflects the crowding effects on key cellular reactions. This phase separation
model needs to be exploited in microfluidic devices in order to mimic the regulatory mechanism
of compartmentalization of biochemical reactions within the cells. Several features can be offered
by the phase separation model for transcriptional control including dynamic changes, clustering of
factors, production of super-enhancers, allowing simultaneous activation of multiple genes by the same
enhancer, and enhancing the sensitivity of super-enhancers against transcriptional inhibitors [121].
Apart from the creation of droplets as a cell-like environment, microfluidic devices themselves
can be used as artificial cells and are recognized as cells-on-a-chip. Karzbrun et al. [109] grafted
DNA brushes on a microfluidic chip. After this, they allowed the continuous flow of the cell-free
reaction mixture in the main channel, resulting in the continuous production of green fluorescent
protein. Using the microfluidic chip as an alternative to vesicles enables the constant influx of
building elements into the channels and collection of reaction products with a high degree of control.
This system allows the study of biological networks in a simplified, controlled, and fully addressable
seminatural environment.
5. Conclusions
Synthetic biology can be defined as the reprogramming of an existing natural system to construct
a seminatural one—even in the absence of living cells. The growth of synthetic biology as a
field integrates high-throughput experiments and screening platforms. The current methods to
engineer cells are costly, time-consuming, and difficult. Exploiting cell-free synthetic biology in
combination with microfluidic technology will provide better engineering solutions and open more
opportunities in different applications from basic (protein biochemistry) to biomedical science to
biofuel research. Cell-free synthetic biology in genome, protein biochemistry, or proteomic fields is
capable of investigating such biological materials by constructing a biosynthetic system without the
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membrane boundaries that account for low efficiencies and misfolding in the conventional cellular
platforms. Indeed, the advanced design of the microfluidic platforms as an integrated system enables
highly controlled gene and protein synthesis by robots that easily handle reagents/samples. Apart from
the precise control, microfluidic devices allow real-time, rapid analysis at a small scale. Cell-on-a-chip
offers a good model to provide modules, resembling the natural context, which may in future reduce
the gap between in vivo and in vitro systems.
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